Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10F | NM | - | Pertuzumab | 0.000016 | mg/ml | 7487.102 | 0.9146 | 0.8864 | 1.5273 | |||
MCF 10F | NM | - | Pertuzumab | 0.002 | mg/ml | 7487.102 | 0.8741 | 0.8313 | 1.5273 | |||
MCF 10F | NM | - | Pertuzumab | 0.01 | mg/ml | 7487.102 | 0.9008 | 0.8678 | 1.5273 | |||
MCF 10F | NM | - | Pertuzumab | 0.25 | mg/ml | 7487.102 | 0.8097 | 0.7418 | 1.5273 | |||
MCF 10F | NM | - | Pertuzumab | 1.25 | mg/ml | 7487.102 | 0.7477 | 0.6533 | 1.5273 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 0.0000032 | mg/ml | 5903.102 | 0.9980 | 0.9969 | 1.2557 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 0.000016 | mg/ml | 5903.102 | 1.0022 | 1.0035 | 1.2557 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 0.0004 | mg/ml | 5903.102 | 1.0655 | 1.1036 | 1.2557 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 0.002 | mg/ml | 5903.102 | 0.9583 | 0.9333 | 1.2557 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 0.25 | mg/ml | 5903.102 | 0.9578 | 0.9324 | 1.2557 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 1.25 | mg/ml | 5903.102 | 1.0659 | 1.1043 | 1.2557 | |||
HBL-100 | Unknown | Unknown | Pertuzumab | 0.000016 | mg/ml | 7429.102 | 1.0384 | 1.0312 | 2.4347 | |||
HBL-100 | Unknown | Unknown | Pertuzumab | 0.00008 | mg/ml | 7429.102 | 1.0304 | 1.0248 | 2.4347 | |||
HBL-100 | Unknown | Unknown | Pertuzumab | 0.05 | mg/ml | 7429.102 | 0.9868 | 0.9892 | 2.4347 | |||
HBL-100 | Unknown | Unknown | Pertuzumab | 0.25 | mg/ml | 7429.102 | 0.9430 | 0.9523 | 2.4347 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 0.0000032 | mg/ml | 7441.102 | 0.9877 | 0.9731 | 0.9144 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 0.000016 | mg/ml | 7441.102 | 1.0278 | 1.0610 | 0.9144 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 0.002 | mg/ml | 7441.102 | 0.9564 | 0.9049 | 0.9144 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 0.01 | mg/ml | 7441.102 | 0.9598 | 0.9122 | 0.9144 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 0.25 | mg/ml | 7441.102 | 0.9604 | 0.9135 | 0.9144 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 1.25 | mg/ml | 7441.102 | 0.9571 | 0.9063 | 0.9144 | |||
HCC1569 | HER2amp | Basal A | Pertuzumab | 0.002 | mg/ml | 7447.102 | 0.9593 | 0.9502 | 1.6467 | |||
HCC1569 | HER2amp | Basal A | Pertuzumab | 0.01 | mg/ml | 7447.102 | 0.9470 | 0.9350 | 1.6467 | |||
MCF12A | NM | Basal B | Pertuzumab | 0.002 | mg/ml | 7489.102 | 0.9273 | 0.9387 | 2.4234 | |||
MCF12A | NM | Basal B | Pertuzumab | 0.0004 | mg/ml | 7489.102 | 0.9913 | 0.9928 | 2.4234 |